Slide 1: Interim Report 3rd Quarter & Nine Months 2025
Interim Report 3rd Quarter & Nine Months 2025 November 19, 2025 NASDAQ STOCKHOLM MAIN LIST (CANTA.ST)
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and
Slide 3: Interim Report Jan – Sep 2025
INTERIM REPORT JAN – SEP 2025 Hilde Steineger Wolfram Dempke Patrik Renblad Chief Executive Officer Chief Medical Officer Chief Financial Officer
Slide 4: Events in the Third Quarter and After the Period
Events in the Third Quarter and After the Period Significant Events in the Third Quarter 2025 • Otsuka Pharmaceuticals acquired CAN10 for an upfront of MUSD 33 plus an additional MUSD 580 in potential milestone payments and up to double digit royalties on future sales. • Preliminary results from the
Slide 5: Otsuka Transaction – CAN10
OTSUKA TRANSACTION – CAN10
Slide 6: Transformational CAN10 Deal with Otsuka
Transformational CAN10 Deal with Otsuka • Marks a transformative milestone for Cantargia – providing external validation of its antibody platform and CAN10 target mechanism • Demonstrates the scientific and commercial value of Cantargia’s technology in autoimmune and inflammatory diseases • Enables
Slide 7: Pipeline & Strategic Focus
PIPELINE & STRATEGIC FOCUS
Slide 8: IL1RAP Pipeline supported by Unique Platform
IL1RAP Pipeline supported by Unique Platform IND Asset Target Indication Discovery Phase 1 Phase 2 Phase 3 Partner Enabling Proprietary Pipeline PDAC* Nadunolimab IL1RAP NSCLC TNBC** CAN14 IL1RAP BsAb*** Autoimmune diseases New development programs**** through CANxx unique IL1RAP platform Strategic
Slide 9: Nadunolimab in PDAC
NADUNOLIMAB IN PDAC
Slide 10: High IL1RAP Expression Linked to Poor Outcome in Patients with Pancreatic Tumors
High IL1RAP Expression Linked to Poor Outcome in Patients with Pancreatic Tumors TCGA RNA data* Know Your Tumor RNA data** BIOPAC biopsy protein stainings*** PDAC patients all stages PDAC patients stage III/IV PDAC patients stage IV Analysis of RNA-data by AI-company show two subnetworks enriched fo
Slide 11: PDAC: A Deadly Cancer with Limited Treatment Options
PDAC: A Deadly Cancer with Limited Treatment Options LOCALLY ADVANCED OR METASTATIC DISEASE Median survival: Stage III → 8.5 – 11.7 mo Treatments: → Gemcitabine + nab-paclitaxel → Gemcitabine if poorer performance → FOLFIRINOX only if good patient condition status → Jan 2023: 1st line NALIRIFOX Stag
Slide 12: Positive Nadunolimab Efficacy Signals in 1st Line PDAC
Positive Nadunolimab Efficacy Signals in 1st Line PDAC OS and iPFS for mITT patients Best responses according to iRECIST 100% Best Change in Tumor Size 50% 0% -50% -100% iCPD iUPD iSD iPR Nadunolimab combination with gemcitabine/nab-paclitaxel in 1st line PDAC (n=73): → 32% response rate with long O
Slide 13: Stronger OS Benefits in High IL1RAP-Expressing Patients
Van Cutsem et al, Clinical Cancer Research 2024 Stronger OS Benefits in High IL1RAP-Expressing Patients (14.2 vs 10.6 months ) OS by IL1RAP subgroup OS by IL1RAP subgroup Efficacy analysis for IL1RAP High (n=29, 60%) vs IL1RAP Low (n=20, 40%) PDAC patients → High IL1RAP expression is a marker for po
Slide 14: Nadunolimab – Key Takeaways
Nadunolimab – Key Takeaways → Nadunolimab, investigated in more than 300 pts, shows promising safety & efficacy. → The mechanism of nadunolimab includes ADCC and blocking of both IL-1α and IL-1β signaling through IL1RAP. → Clinical results strongly support potential unique first-in-class opportuniti
Slide 15: CAN14 & CANxx
CAN14 & CANXX
Slide 16: Next Generation IL1RAP Therapeutics
Next Generation IL1RAP Therapeutics Anti-IL1RAP IL1RAP blockade is a potent way to block inflammation in preclinical and translational ex vivo models Bispecific mAbs Add new functionalities to IL1RAP blockade for stronger efficacy – tailor for specific diseases Second target IL1RAP is expressed in a
Slide 17: Financial Results
FINANCIAL RESULTS
Slide 18: Cantargia Reports First Ever Revenue & Profit
Cantargia Reports First Ever Revenue & Profit MSEK Quarter 3 2025 41.7 1.5 308.7 267.0 265.5 Revenues Operating Expenses Operating Result Net Financial Items Profit for the Period Earnings per share: 1.07 SEK 18
Slide 19: Cantargia Reports First Ever Revenue & Profit
Cantargia Reports First Ever Revenue & Profit MSEK Year-to-Date September 2025 126.2 3.2 308.7 182.5 179.3 Revenues Operating Expenses Operating Result Net Financial Items Profit for the Period Earnings per share: 0.72 SEK 19
Slide 20: Operating Expenses in the Quarter and Year-to-Date
Operating Expenses in the Quarter and Year-to-Date 127.9 126.2 100.2 42.4 41.7 R&D 117.1 24.8 R&D 38.9 16.8 26.0 Admin&Other 3.5 Admin&Other 10.7 2024 Q3 2025 Q3 2024 9M 2025 9M Q3 9M 20
Slide 21: Cash Flow and Cash Position
Cash Flow and Cash Position MSEK Operating Cash Flow 339 SEK 281m (Q3, 2024: SEK -44.4m) Available funds SEK 339m 140 (September 30, 2024: SEK 60m) 104 107 82 Cash Runway 60 104 Current available funds are expected to fund… 60 • Ongoing commitments on nadunolimab (but not 33 0 0 0 a pivotal program)
Slide 22: Closing Remarks and Q&A
CLOSING REMARKS AND Q&A
Slide 23: A Global Leader in IL1RAP Antibody Development
A Global Leader in IL1RAP Antibody Development Potential to become best-in-class in 1L PDAC: Lead Candidate Nadunolimab ready to start pivotal trials on the back of outstanding efficacy and safety POC results, especially in high IL1RAP-expressing tumors; FDA Fast Track and Orphan Drug designations s
Slide 24: Thank You!
THANK YOU!